[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053225":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":30,"locations":37,"responsibleParty":126,"collaborators":35,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":35,"eligibilityCriteria":134,"healthyVolunteers":130,"sex":135,"minAge":136,"maxAge":35,"enrollmentInfo":137,"targetDuration":35,"studyType":140,"phases":141,"briefSummary":144,"conditions":145,"keywords":35,"overallStatus":40,"whyStopped":35,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: Pembrolizumab in Pediatric Participants with Solid Tumors or Lymphomas","EXPERIMENTAL","Pediatric participants with solid tumors or lymphomas receive 2 mg\u002Fkg pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 17 or 35 cycles.",[13],"Biological: Pembrolizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: Pembrolizumab in Adult Participants with Merkel Cell Carcinoma (MCC)","Adult participants with MCC receive 400 mg pembrolizumab via IV infusion on Day 1 of each 42 day (6 week) cycle, for up to 18 cycles.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Pembrolizumab","25 mg\u002FmL solution for intravenous infusion.",[9,15],[25],"MK-3475",[27],{"name":28,"affiliation":5,"role":29},"Medical Director","STUDY_DIRECTOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Toll Free Number","CONTACT","1-888-577-8839",null,"Trialsites@msd.com",[38,56,63,76,89,102,114],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Nagoya City University Hospital ( Site 0003)","RECRUITING","Nagoya","Aichi-ken","467-8602","Japan","JP",{"type":47,"coordinates":48},"Point",[49,50],136.90641,35.18147,{"lat":50,"lon":49},[53],{"name":54,"role":33,"phone":55,"phoneExt":35,"email":35},"Study Coordinator","+81-52-851-5511",{"facility":57,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Nagoya City University Hospital ( Site 0007)",{"type":47,"coordinates":59},[49,50],{"lat":50,"lon":49},[62],{"name":54,"role":33,"phone":55,"phoneExt":35,"email":35},{"facility":64,"status":40,"city":65,"state":66,"zip":67,"country":44,"countryCode":45,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Sapporo Hokuyu Hospital ( Site 0005)","Sapporo","Hokkaido","003-0006",{"type":47,"coordinates":69},[70,71],141.35,43.06667,{"lat":71,"lon":70},[74],{"name":54,"role":33,"phone":75,"phoneExt":35,"email":35},"+81-11-865-0111",{"facility":77,"status":40,"city":78,"state":79,"zip":80,"country":44,"countryCode":45,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Hyogo Prefectural Kobe Children's Hospital ( Site 0006)","Kobe","Hyōgo","650-0047",{"type":47,"coordinates":82},[83,84],135.183,34.6913,{"lat":84,"lon":83},[87],{"name":54,"role":33,"phone":88,"phoneExt":35,"email":35},"+81-78-945-7300",{"facility":90,"status":40,"city":91,"state":92,"zip":93,"country":44,"countryCode":45,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"National Cancer Center Hospital ( Site 0002)","Chūō","Tokyo","104-0045",{"type":47,"coordinates":95},[96,97],139.77544,35.67004,{"lat":97,"lon":96},[100],{"name":54,"role":33,"phone":101,"phoneExt":35,"email":35},"+81-3-3542-2511",{"facility":103,"status":40,"city":104,"state":35,"zip":105,"country":44,"countryCode":45,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"National Hospital Organization Kyushu Cancer Center ( Site 0001)","Fukuoka","811-1395",{"type":47,"coordinates":107},[108,109],130.41667,33.6,{"lat":109,"lon":108},[112],{"name":54,"role":33,"phone":113,"phoneExt":35,"email":35},"+81-92-541-3231",{"facility":115,"status":40,"city":116,"state":35,"zip":117,"country":44,"countryCode":45,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"University Hospital,Kyoto Prefectural University of Medicine ( Site 0004)","Kyoto","602-8566",{"type":47,"coordinates":119},[120,121],135.75385,35.02107,{"lat":121,"lon":120},[124],{"name":54,"role":33,"phone":125,"phoneExt":35,"email":35},"+81-75-251-5111",{"type":127,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100053225","phase-1-a-study-of-pembrolizumab-in-japanese-pediatric-participants-with-solid-tumors-or-lymphomas-and-japanese-adult-participants-with-merkel-cell-carcinoma-mk-3475-g21keynote-g21-100053225",false,"NCT07302347","A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21\u002FKEYNOTE-G21)","A Phase I\u002FII Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\nArm 1:\n\n* For participants with relapsed or refractory classical Hodgkin lymphoma (cHL) or primary mediastinal large B-cell lymphoma (PMBCL)\n\n  * Has a confirmed diagnosis of relapsed or refractory cHL or PMBCL after the most recent therapy\n  * Has radiographically measurable disease per Lugano classification\n* For participants with completely resected melanoma:\n\n  * Has surgically completely resected and histologically\u002Fpathologically confirmed diagnosis of Stage IIB, IIC, III or IV cutaneous melanoma\n  * Has not received any prior systemic therapy for their melanoma beyond surgical resection\n  * All suspicious lesions amenable to biopsy are confirmed negative for malignancy\n* For participants with locally advanced or metastatic melanoma:\n\n  * Has histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma (including acral) not amenable to local therapy\n  * Has radiographically measurable lesion(s) as defined by RECIST 1.1\n* For participants with microsatellite instability-high (MSI-H)\u002Fmismatch repair deficiency (dMMR) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has a documented positive local MSI-H or dMMR test result\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with tumor mutational burden-high (TMB-H) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with MCC:\n\n  * Has histologically confirmed diagnosis of locoregional MCC that has recurred following standard locoregional therapy with surgery and\u002For radiation therapy and is not amenable to local therapy or metastatic MCC (Stage IV)\n  * Has radiographically measurable disease based on RECIST 1.1\n\nArm 2:\n\n* For participants with MCC:\n\n  * Has been untreated for advanced or metastatic disease\n\nArm 1 \\& Arm 2:\n\n* Life expectancy of \\>3 months (Arm 1) or \\>6 months (Arm 2)\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has known additional malignancy that is progressing or has required active treatment\n* Has known active (central nervous system) CNS metastases and\u002For carcinomatous meningitis\n* Has active autoimmune disease that has required systemic treatment in past 2 years\n* Has history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has active infection requiring systemic therapy\n* Has known history of human immunodeficiency virus (HIV) infection\n* Has known history of Hepatitis B infection or known active Hepatitis C virus\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years\n* Has not adequately recovered from major surgery or has ongoing surgical complications","ALL","6 Months",{"count":138,"type":139},20,"ESTIMATED","INTERVENTIONAL",[142,143],"PHASE1","PHASE2","Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn:\n\n* About the safety of pembrolizumab (the study medicine) and if people tolerate it\n* What happens to different doses of pembrolizumab in a person's body over time\n* How the cancer responds (gets smaller or goes away) to treatment",[146,147,148],"Malignant Neoplasm","Carcinoma, Merkel Cell","Lymphoma","2026-07-10",{"date":151,"type":152},"2026-07-13","ACTUAL",{"date":154,"type":152},"2026-06-23",{"date":156,"type":139},"2029-12-31",{"name":5,"class":6},7]